Research ArticleArticle
Open Access
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra S. Steinberg, Bradley D. Vince, Yun-Jung Choi, Robert L. Martin, Charles A. McWherter and Pol F. Boudes
The Journal of Rheumatology December 2016, jrheum.161062; DOI: https://doi.org/10.3899/jrheum.161062
Alexandra S. Steinberg
From CymaBay Therapeutics Inc., Newark, California; Vince and Associates, Overland Park, Kansas, USA. A.S. Steinberg, MD, PhD, CymaBay Therapeutics Inc.; B.D. Vince, DO, Vince and Associates; Y.J. Choi, PhD, CymaBay Therapeutics Inc.; R.L. Martin, PhD, CymaBay Therapeutics Inc.; C.A. McWherter, PhD, CymaBay Therapeutics Inc.; P.F. Boudes, MD, CymaBay Therapeutics Inc. Address correspondence to Dr. P.F. Boudes, CymaBay Therapeutics, Inc., 7999 Gateway Blvd., Suite 130, Newark, California 94560, USA. E-mail: pboudes@cymabay.com. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 4, 2016.
Bradley D. Vince
From CymaBay Therapeutics Inc., Newark, California; Vince and Associates, Overland Park, Kansas, USA. A.S. Steinberg, MD, PhD, CymaBay Therapeutics Inc.; B.D. Vince, DO, Vince and Associates; Y.J. Choi, PhD, CymaBay Therapeutics Inc.; R.L. Martin, PhD, CymaBay Therapeutics Inc.; C.A. McWherter, PhD, CymaBay Therapeutics Inc.; P.F. Boudes, MD, CymaBay Therapeutics Inc. Address correspondence to Dr. P.F. Boudes, CymaBay Therapeutics, Inc., 7999 Gateway Blvd., Suite 130, Newark, California 94560, USA. E-mail: pboudes@cymabay.com. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 4, 2016.
Yun-Jung Choi
From CymaBay Therapeutics Inc., Newark, California; Vince and Associates, Overland Park, Kansas, USA. A.S. Steinberg, MD, PhD, CymaBay Therapeutics Inc.; B.D. Vince, DO, Vince and Associates; Y.J. Choi, PhD, CymaBay Therapeutics Inc.; R.L. Martin, PhD, CymaBay Therapeutics Inc.; C.A. McWherter, PhD, CymaBay Therapeutics Inc.; P.F. Boudes, MD, CymaBay Therapeutics Inc. Address correspondence to Dr. P.F. Boudes, CymaBay Therapeutics, Inc., 7999 Gateway Blvd., Suite 130, Newark, California 94560, USA. E-mail: pboudes@cymabay.com. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 4, 2016.
Robert L. Martin
From CymaBay Therapeutics Inc., Newark, California; Vince and Associates, Overland Park, Kansas, USA. A.S. Steinberg, MD, PhD, CymaBay Therapeutics Inc.; B.D. Vince, DO, Vince and Associates; Y.J. Choi, PhD, CymaBay Therapeutics Inc.; R.L. Martin, PhD, CymaBay Therapeutics Inc.; C.A. McWherter, PhD, CymaBay Therapeutics Inc.; P.F. Boudes, MD, CymaBay Therapeutics Inc. Address correspondence to Dr. P.F. Boudes, CymaBay Therapeutics, Inc., 7999 Gateway Blvd., Suite 130, Newark, California 94560, USA. E-mail: pboudes@cymabay.com. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 4, 2016.
Charles A. McWherter
From CymaBay Therapeutics Inc., Newark, California; Vince and Associates, Overland Park, Kansas, USA. A.S. Steinberg, MD, PhD, CymaBay Therapeutics Inc.; B.D. Vince, DO, Vince and Associates; Y.J. Choi, PhD, CymaBay Therapeutics Inc.; R.L. Martin, PhD, CymaBay Therapeutics Inc.; C.A. McWherter, PhD, CymaBay Therapeutics Inc.; P.F. Boudes, MD, CymaBay Therapeutics Inc. Address correspondence to Dr. P.F. Boudes, CymaBay Therapeutics, Inc., 7999 Gateway Blvd., Suite 130, Newark, California 94560, USA. E-mail: pboudes@cymabay.com. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 4, 2016.
Pol F. Boudes
From CymaBay Therapeutics Inc., Newark, California; Vince and Associates, Overland Park, Kansas, USA. A.S. Steinberg, MD, PhD, CymaBay Therapeutics Inc.; B.D. Vince, DO, Vince and Associates; Y.J. Choi, PhD, CymaBay Therapeutics Inc.; R.L. Martin, PhD, CymaBay Therapeutics Inc.; C.A. McWherter, PhD, CymaBay Therapeutics Inc.; P.F. Boudes, MD, CymaBay Therapeutics Inc. Address correspondence to Dr. P.F. Boudes, CymaBay Therapeutics, Inc., 7999 Gateway Blvd., Suite 130, Newark, California 94560, USA. E-mail: pboudes@cymabay.com. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 4, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra S. Steinberg, Bradley D. Vince, Yun-Jung Choi, Robert L. Martin, Charles A. McWherter, Pol F. Boudes
The Journal of Rheumatology Dec 2016, jrheum.161062; DOI: 10.3899/jrheum.161062
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra S. Steinberg, Bradley D. Vince, Yun-Jung Choi, Robert L. Martin, Charles A. McWherter, Pol F. Boudes
The Journal of Rheumatology Dec 2016, jrheum.161062; DOI: 10.3899/jrheum.161062